Thursday, August 29, 2013
diabetes deal with the Sanford-Burnham Medical Research Institute could help reverse a trend that has seen the pharma
arriving late-or not at all-to the party with new targets for the indication.
Indeed, the goal of the three-year collaboration is to identify and validate
new drug targets to prevent and treat insulin resistance and organ damage in
Haas, M.J. SciBX 6(33); doi:10.1038/scibx.2013.880 Published online Aug.
1. Nallanathan, B. BioCentury
21(18), A9-A12; May 6, 2013
2. Cain, C. SciBX 3(46);
3. Haas, M.J. SciBX
AND INSTITUTIONS MENTIONED
Florida Hospital, Orlando, Fla.
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Sanford-Burnham Medical Research Institute, La Jolla, Calif.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
The Translational Research Institute for Metabolism and
Diabetes, Winter Park,